APYX vs HAE
APYX: Apyx Medical provides advanced helium plasma-based surgical technology for cosmetic body contouring and hospital-based electrosurgical procedures. HAE: Haemonetics provides automated plasma collection systems, blood processing devices, and hospital blood management technologies serving plasma centers, blood banks, and hospitals globally.
Side-by-side fundamentals
| Metric | APYX | HAE | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $3.89 | $79.91 | |
| Market cap as of 2026-07-31 | $163M | $3.8B | |
| P/E as of 2026-07-31 | n/a | 39.27 | |
| Net margin as of 2026-07-31 | -16.4% | +7.3% | HAE higher |
| Gross margin as of 2026-07-31 | +63.1% | +59.0% | APYX higher |
| Operating margin as of 2026-07-31 | -7.7% | +11.8% | HAE higher |
| ROE as of 2026-07-31 | -90.6% | +11.3% | HAE higher |
| ROA as of 2026-07-31 | -14.9% | +4.0% | HAE higher |
| Debt / equity as of 2026-07-31 | 2.74 | 1.54 | HAE lower |
| Revenue growth (YoY) as of 2026-07-31 | +18.2% | -2.0% | APYX higher |
| Revenue CAGR (3y) SEC XBRL | +5.9% | +4.5% | APYX higher |
| Beta as of 2026-07-31 | 1.42 | 0.50 | |
| 1-year return as of 2026-07-27 close | +53.1% | +6.3% | APYX higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.